Atlas Trials

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Clinical trial NCT00050843 · COMPLETED

Trial details

NCT number
NCT00050843
Sponsor
Celgene Corporation
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Myelodysplastic Syndromes
Start date
2001-08-01
Enrollment
220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.